Sublinox approved in Canada

Sublinox approved in Canada

The Canadian regulatory authority (Health Canada) has approved Sublinox
for treatment of insomnia. Sublinox is a new and patented sublingual
product with the well known substance zolpidem. The product will be
commercialized by the joint venture between Meda and Valeant (Meda
Valeant Pharma Canada Inc.). Sublinox launch is expected to begin during
the fourth quarter of 2011.

“I'm pleased that we have now received our second product approval in
Canada. We look forward to strengthen our joint venture with Valeant in
Canada”, says Anders Lönner, CEO of Meda.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878